# Clinical Cases: Neoplasia - Basic Concepts

## Case 1: Colorectal Adenocarcinoma with Multi-Step Carcinogenesis

### Patient Demographics
- **Age:** 58 years old
- **Sex:** Male
- **Occupation:** Office manager

### Chief Complaint
"Blood in my stool and change in bowel habits for 3 months"

### History of Present Illness
A 58-year-old male presents with a 3-month history of intermittent bright red blood mixed with stool. He has noticed a change in bowel habits with alternating constipation and diarrhea, narrower caliber stools, and a sensation of incomplete evacuation. He reports unintentional weight loss of 8 kg over the past 4 months and progressive fatigue. His father was diagnosed with colon cancer at age 62. The patient had never undergone colonoscopy screening.

### Physical Examination
- **Vital Signs:** BP 128/78 mmHg, HR 88 bpm, RR 16/min, Temp 37.1C
- **General:** Thin male appearing fatigued, no acute distress
- **Abdomen:** Soft, mild tenderness in left lower quadrant, no palpable masses, no hepatomegaly
- **Rectal:** Palpable mass on digital rectal examination, guaiac-positive stool
- **Lymph nodes:** No palpable adenopathy

### Diagnostic Workup

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| Hemoglobin | 9.8 g/dL | 13.5-17.5 g/dL |
| MCV | 72 fL | 80-100 fL |
| Iron | 35 mcg/dL | 60-170 mcg/dL |
| Ferritin | 12 ng/mL | 30-400 ng/mL |
| CEA | 45 ng/mL | <3 ng/mL |

**Colonoscopy:**
- Large, ulcerated, circumferential mass in the sigmoid colon causing partial luminal obstruction
- Multiple polyps in ascending colon (biopsied)

**CT Abdomen/Pelvis:**
- 5 cm sigmoid colon mass with extramural extension
- Two hypodense liver lesions (2.1 cm and 1.4 cm) concerning for metastases
- Enlarged pericolonic lymph nodes

**Biopsy Pathology:**
- **Sigmoid mass:** Moderately differentiated adenocarcinoma with glandular architecture
- **Ascending colon polyps:** Tubular adenoma with high-grade dysplasia

### Pathology Correlation
This case exemplifies the **adenoma-carcinoma sequence** of colorectal cancer:

**Multi-Step Carcinogenesis:**
1. **APC gene inactivation** (early event) - Loss of tumor suppressor leads to increased beta-catenin and cell proliferation
2. **KRAS mutation** - Oncogene activation drives adenoma growth
3. **SMAD4 loss** - Further tumor suppressor inactivation
4. **TP53 mutation** (late event) - "Guardian of the genome" loss enables genomic instability and invasion

**Tumor Characteristics:**
- **Parenchyma:** Neoplastic glandular cells forming irregular, infiltrating glands
- **Stroma:** Desmoplastic response with fibrosis surrounding tumor glands
- **Grade:** Moderately differentiated (Grade 2) - maintains some glandular architecture
- **Metastasis:** Liver metastases via portal venous drainage (common pathway)

**Key Hallmarks Demonstrated:**
- Sustaining proliferative signaling (KRAS activation)
- Evading growth suppressors (APC, TP53 loss)
- Activating invasion and metastasis
- Inducing angiogenesis

### Clinical Image
![Colorectal Carcinoma - Gross Pathology](case_01_image.jpg)

*Gross pathology of colorectal carcinoma showing an ulcerated, infiltrating mass in the colonic wall. The tumor demonstrates raised, rolled edges with central ulceration, consistent with an adenocarcinoma.*

**Image Source:** Wikimedia Commons - "Colon cancer"
**License:** CC BY-SA 3.0
**URL:** https://commons.wikimedia.org/wiki/File:Colon_cancer_2.jpg

### Diagnosis
**Stage IV Colorectal Adenocarcinoma** (T3N1M1a - liver metastases)

### Treatment
1. Molecular profiling (RAS/BRAF status, MSI testing)
2. Neoadjuvant chemotherapy (FOLFOX or FOLFIRI)
3. Consider targeted therapy based on molecular profile:
   - Anti-VEGF (bevacizumab) if RAS mutant
   - Anti-EGFR (cetuximab) if RAS wild-type
4. Surgical resection of primary tumor if good response
5. Liver-directed therapy for metastases

### Teaching Points
1. **Multi-step carcinogenesis** requires accumulation of multiple genetic alterations over years
2. The **adenoma-carcinoma sequence** demonstrates progression from benign to malignant
3. **Driver mutations** (APC, KRAS, TP53) confer growth advantage; **passenger mutations** accumulate passively
4. **Clonal evolution** creates tumor heterogeneity and therapy resistance
5. **Tumor markers** (CEA) are useful for monitoring but not screening
6. Family history increases colorectal cancer risk - screening guidelines recommend colonoscopy at age 45

---

## Case 2: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

### Patient Demographics
- **Age:** 45 years old
- **Sex:** Female
- **Occupation:** Accountant

### Chief Complaint
"Abdominal fullness and fatigue for 2 months"

### History of Present Illness
A 45-year-old female presents with progressive fatigue and a sensation of fullness in the left upper abdomen for the past 2 months. She reports early satiety and occasional left shoulder discomfort after eating. She has experienced night sweats and has lost 5 kg unintentionally. She denies fever, bleeding, or bruising. She has no significant past medical history.

### Physical Examination
- **Vital Signs:** BP 118/74 mmHg, HR 82 bpm, RR 14/min, Temp 37.0C
- **General:** Mild pallor, no acute distress
- **Abdomen:** Massive splenomegaly with spleen palpable 12 cm below left costal margin, crossing midline; mild hepatomegaly
- **Lymph nodes:** No significant lymphadenopathy
- **Skin:** No petechiae or ecchymoses

### Diagnostic Workup

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| WBC | 185,000/uL | 4,500-11,000/uL |
| Hemoglobin | 10.2 g/dL | 12-16 g/dL |
| Platelets | 485,000/uL | 150,000-400,000/uL |
| Basophils | 8% | 0-1% |
| LAP score | 15 | 70-170 |

**Peripheral Blood Smear:**
- Marked leukocytosis with full spectrum of myeloid maturation
- Increased basophils and eosinophils
- Myelocytes and metamyelocytes present
- No significant dysplasia

**Bone Marrow Biopsy:**
- Hypercellular (95%) with myeloid predominance
- M:E ratio 15:1
- Increased megakaryocytes, some small hypolobated forms

**Cytogenetics:**
- t(9;22)(q34;q11) - Philadelphia chromosome present in 100% of metaphases

**Molecular Testing:**
- BCR-ABL1 fusion gene positive (p210 transcript)
- BCR-ABL1/ABL1 ratio: 85%

### Pathology Correlation
This case demonstrates **oncogene activation through chromosomal translocation**:

**The Philadelphia Chromosome:**
- **Translocation t(9;22)** creates fusion of BCR gene (chromosome 22) with ABL1 gene (chromosome 9)
- **BCR-ABL1 fusion protein** is a constitutively active tyrosine kinase
- Unlike normal ABL, which cycles between active and inactive states, BCR-ABL is "always on"

**Oncogenic Mechanisms:**
1. **Constitutive tyrosine kinase activity** - drives continuous cell proliferation
2. **Activation of RAS/MAPK pathway** - promotes growth signals
3. **Activation of PI3K/AKT pathway** - promotes cell survival
4. **Inhibition of apoptosis** - prevents normal cell death

**Disease Phases:**
- **Chronic phase:** Excessive but functional granulocyte production
- **Accelerated phase:** Increasing blasts, genomic instability
- **Blast crisis:** Acute leukemia (additional mutations, often TP53)

**Targeted Therapy Revolution:**
Imatinib (Gleevec) specifically inhibits BCR-ABL tyrosine kinase activity - the paradigm for **targeted therapy** based on understanding molecular pathogenesis.

### Clinical Image
![BCR-ABL Pathway](case_02_image.jpg)

*Diagram illustrating the Philadelphia chromosome translocation t(9;22) creating the BCR-ABL fusion gene, which encodes a constitutively active tyrosine kinase driving uncontrolled proliferation in CML.*

**Image Source:** Wikimedia Commons - "Philadelphia chromosome"
**License:** Public Domain
**URL:** https://commons.wikimedia.org/wiki/File:Philadelphia_chromosome.svg

### Diagnosis
**Chronic Myeloid Leukemia, BCR-ABL1 positive, Chronic Phase**

### Treatment
1. Tyrosine kinase inhibitor (TKI) therapy:
   - First-line: Imatinib 400 mg daily, OR
   - Second-generation TKI (dasatinib, nilotinib) for faster/deeper response
2. Monitor BCR-ABL1 transcript levels by quantitative PCR
3. Milestone assessments:
   - 3 months: BCR-ABL <10% (Early Molecular Response)
   - 12 months: BCR-ABL <0.1% (Major Molecular Response)
4. Consider TKI discontinuation if sustained deep molecular response

### Teaching Points
1. **Chromosomal translocations** can activate oncogenes by creating fusion proteins or dysregulating gene expression
2. The **Philadelphia chromosome** represents the paradigm of targeted therapy development
3. **BCR-ABL** is a classic example of an oncogene encoding a **constitutively active signaling molecule**
4. Understanding molecular pathogenesis enables development of **precision medicine**
5. TKIs have transformed CML from a fatal disease to a manageable chronic condition
6. **Drug resistance** can develop through ABL kinase domain mutations, requiring alternative TKIs